Inovio Pharmaceuticals, Inc. (0A43.L)
| Previous close | 11.09 |
| Open | 11.07 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 10.16 - 11.15 |
| 52-week range | 0.33 - 12.71 |
| Volume | |
| Avg. volume | 28,855 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of $7.693 per share and pre-funded warrants to purchase 2,135,477 shares of its common stock at an offering price of $7.692 per pre-funded warrant, in each case befor
- PR Newswire
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO will participate in The Novel Therapeutics Forum hosted by Citizens JMP at Penn Medicine at 10:00 am ET on April 2, 2024.
- PR Newswire
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results and operational highlights for the fourth quarter and full year ended December 31, 2023.
